Bone Therapeutics is planning a Phase II trial with ALLOB® allogeneic “off the shelf” bone cell therapy for the treatment of severe osteoporosis.
The trial supplants a previous Phase IIA trial of PREOB® autologous therapy for the same indication. Company leadership noted that ALLOB presents advantages in dosing, logistics and scalability, which may make it an easier product to commercialize for use by a larger patient population.
PREOB remains in pivotal Phase IIB/III clinical studies for osteonecrosis and non-union fracture indications. The Phase II ALLOB trial is expected to commence in early 2017.
Bone Therapeutics is planning a Phase II trial with ALLOB® allogeneic “off the shelf” bone cell therapy for the treatment of severe osteoporosis.
The trial supplants a previous Phase IIA trial of PREOB® autologous therapy for the same indication. Company leadership noted that ALLOB presents advantages in dosing, logistics and scalability,...
Bone Therapeutics is planning a Phase II trial with ALLOB® allogeneic “off the shelf” bone cell therapy for the treatment of severe osteoporosis.
The trial supplants a previous Phase IIA trial of PREOB® autologous therapy for the same indication. Company leadership noted that ALLOB presents advantages in dosing, logistics and scalability, which may make it an easier product to commercialize for use by a larger patient population.
PREOB remains in pivotal Phase IIB/III clinical studies for osteonecrosis and non-union fracture indications. The Phase II ALLOB trial is expected to commence in early 2017.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
